Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions

Zhejiang Cancer Hospital64 enrolled

Overview

Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.

The patients enrolled will received 4-6 cycles chemotherapy at first.Then, radical radiotherapy for nasopharyngeal tumors and local treatments for oligometastatic lesions will assigned to those patients. The efficacy and side-effect will be evaluated and analyzed.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Cancer Neoplasm Metastasis

Interventions

radical radiotherapyRADIATION

radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Histologically conformed initial non-keratinizing squamous carcinoma in nasopharynx. 2. Clinical stages,T1-4N0-3M1，IVc(AJCC 2010). 3. The metastatic lesions ≤5 and metastatic organs ≤2 4. Karnofsky scores \>70 5. Normal hemodynamic indices before the recruitment (including white blood cell count\>4.0×109/L, neutrophil count\>1.5×109/L, platelet count \>100×109/L, hemoglobin≥90g/l, normal liver/kidney function). 6. Informed consent signed. Exclusion Criteria: 1. Histologically conformed initial keratinizing carcinoma or others. 2. The metastatic lesions \>5 or metastatic organs \>2. 3. Any severe complications contraindicated chemotherapy or radiotherapy. 4. History of malignant tumors. 5. Pregnant or nursing women. 6. History of radiotherapy or chemotherpy in head and neck regions. 7. Patients refused the informed consent.

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

Overall survival

Events of death caused by any reasons

Time frame: From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months

Secondary Outcomes

Progress free survival

adverse event including death, recurrence and metastases.

Time frame: From date of diagnosis until the date of first documented progression, assessed up to 36 months

Central Contacts

Shuang Huang, Dr

CONTACT

+8618258111085 huangshuang@zjcc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.